At MDRNA we are focused on realizing the potential of RNAi-based therapeutics through the development of a broad-based, state-of-the-art drug discovery platform built upon industry leading expertise in RNA chemistry and oligonucleotide delivery. We bring optimal value to our partners, shareholders and ultimately to patients through the discovery and development of RNAi-based therapeutics against critical unmet medical needs in oncology.

08 February 2010: MDRNA, Inc. Reports Positive Results for Its Proprietary siRNA Delivery Technology

08 February 2010: MDRNA, Inc. Receives Compliance Extension From NASDAQ